pembrolizumab - Robuta Search

https://ascopost.com/issues/february-10-2023/lenvatinib-and-pembrolizumab-in-previously-treated-patients-with-advanced-endometrial-carcinoma/ Lenvatinib and Pembrolizumab in Previously Treated Patients With Advanced Endometrial Carcinoma -... In an analysis reported in the Journal of Clinical Oncology, Vicky Makker, MD, and colleagues provided updated findings from the phase Ib/II Study... pembrolizumab previously treated patients advanced https://adisinsight.springer.com/drugsafety/803927146?error=cookies_not_supported&code=e206605a-2a91-430c-b9eb-7e5863eecd27 Pembrolizumab - AdisInsight A 78-year-old woman with stage IVb squamous-cell carcinoma of the lung and idiopathic pulmonary fibrosis received a first dose of pembrolizumab [dose not pembrolizumab https://jnccn360.org/advanced-skin-cancers/medical-literature/keynote-716-trial-update-adjuvant-pembrolizumab-in-resected-stage-iib-or-iic-melanoma/ JNCCN 360 - Advanced Skin Cancers - KEYNOTE-716 Trial Update: Adjuvant Pembrolizumab in Resected... advanced skin jnccn cancers keynote trial https://www.clinrol.com/study/469 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475)... Researchers are studying sac-TMT and pembrolizumab for advanced pMMR endometrial cancer to see if combined treatment improves survival. a study compare mk combination pembrolizumab https://scholars.duke.edu/publication/1480780 Scholars@Duke publication: Single-arm phase II study of low-dose paclitaxel and pembrolizumab in... single arm phase ii low dose scholars duke https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10668&r=1 Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck... Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma head and neck pembrolizumab alone combination pd https://www.trialx.com/clinical-trials/listings/320086/study-of-pembrolizumab-carboplatin-paclitaxel-and-radiation-for-the-treatment-of-early-stage-anal-cancer/ Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage... Clinical trial for Anal Cancer , Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer for the early stage study pembrolizumab paclitaxel https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/pembrolizumab-2?versie=versie-2 Pembrolizumab | Horizonscan geneesmiddelen Pembrolizumab in combination with Bacillus Calmette-Guerin for adjuvant treatment of high risk non-muscle invasive bladder cancer in adults and elderly who... horizonscan geneesmiddelen pembrolizumab https://visualping.io/pages/lenvatinib-pembrolizumab-in-hepatobiliary-tumors-clinical-trial-alerts-4959732 Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial: Get alerts for the latest updates... See the latest updates to Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial. Subscribe for free to get alerts when changes are detected to... for the latest hepatobiliary tumors clinical trial get alerts pembrolizumab https://www.merckclinicaltrials.com/estudios/nct06036836/?lang=es Estudio de favezelimab coformulado con pembrolizumab en participantes con determinados tumores... Feb 27, 2025 - The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as... estudio de con pembrolizumab en https://ecancer.org/en/news/17062-sabcs-2019-neoadjuvant-and-adjuvant-treatment-with-pembrolizumab-improves-pathologic-complete-response-rates-for-patients-with-triple-negative-breast-cancer-with-lymph-node-involvement SABCS 2019: Neoadjuvant and adjuvant treatment with pembrolizumab improves pathologic complete... The addition of the anti-PD-1 immunotherapeutic pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased the rates of pathologic complete adjuvant treatment sabcs pembrolizumab improves pathologic https://www.esmo.org/meeting-calendar/elcc-2018-lung-cancer/industry-sponsored-satellite-symposia/pembrolizumab-the-new-standard-of-care-in-advanced-lung-cancer Pembrolizumab: The New Standard of Care in Advanced Lung Cancer | ESMO the new standard lung cancer pembrolizumab care advanced https://ctv.veeva.com/study/cetuximab-and-pembrolizumab-in-treating-patients-with-colorectal-cancer-that-is-metastatic-or-cannot Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or... This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer... colorectal cancer pembrolizumab treating patients metastatic https://pure.skku.edu/en/publications/high-pd-l1-expression-is-associated-with-therapeutic-response-to-/ High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with... is associated with in patients high pd expression https://pubmed.ncbi.nlm.nih.gov/38446675/?dopt=Abstract Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or... urothelial cancer pembrolizumab advanced https://scholars.mssm.edu/en/publications/effect-of-pd-l1-testing-on-the-cost-effectiveness-and-budget-impa/ Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced... on the cost effectiveness for advanced pd testing https://scholar.usuhs.edu/en/publications/dose-optimization-of-pembrolizumab-less-may-be-more/ Dose Optimization of Pembrolizumab: Less May Be More - Uniformed Services University may be uniformed services dose optimization pembrolizumab https://www.diagnijmegen.nl/publications/spro22/ Deep learning-based quantification of immune infiltrate for predicting response to pembrolizumab... deep learning based quantification immune infiltrate https://www.ilcn.org/benefit-to-pembrolizumab-observed-in-previously-treated-malignant-pleural-mesothelioma-irrespective-of-pd-l1-status/ Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective... Dec 27, 2021 - Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated... pleural mesothelioma benefit pembrolizumab observed previously https://christie.openrepository.com/entities/publication/95b10ce8-2413-4a5f-ac6e-04427d072e3f Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant... Background: Chemotherapy-naive patients (pts) with mCRPC who had disease progression with enza were enrolled in C4 and C5 of the multicohort phase II KEYNOTE-... phase ii study pembrolizumab plus enzalutamide https://www.zorginstituutnederland.nl/documenten/2016/11/25/advies-acp---beoordeling-pembrolizumab-keytruda Advies ACP - Beoordeling pembrolizumab (Keytruda) | Zorginstituut Nederland zorginstituut nederland advies acp beoordeling pembrolizumab https://connect.uclahealth.org/dom/2025/08/03/intratumoral-vidutolimod-as-monotherapy-or-in-combination-with-pembrolizumab-in-patients-with-programmed-cell-death-1-blockade-resistant-melanoma-final-analysis-from-a-phase-1b-study/ Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with... Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, [...] combination pembrolizumab patients https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-single-agent-pembrolizumab-for-high-risk-early-stage-triple-negative-breast-cancer-in-the-united-states/ Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent... cost effectiveness single agent pembrolizumab plus chemotherapy https://www.avera.org/research-and-clinical-trials/clinical-trials/detail/?id=70 S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as... This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic... phase ii clinical trial olaparib pembrolizumab vs https://researchinformation.umcutrecht.nl/en/publications/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melan/ Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054):... adjuvant pembrolizumab versus placebo stage https://www.2minutemedicine.com/pembrolizumab-with-radiotherapy-and-surgery-improves-survival-in-high-risk-soft-tissue-sarcoma/ Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma | 2... Dec 18, 2024 - 1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common in the... soft tissue sarcoma high risk pembrolizumab radiotherapy surgery https://www.mednet.nl/congres-nieuws/pembrolizumab-effectief-bij-hoogrisico-niet-invasief-urotheelcelcarcinoom-zonder-respons-op-bcg/ Pembrolizumab effectief bij hoogrisico, niet-invasief urotheelcelcarcinoom zonder respons op BCG |... Feb 21, 2023 - Pembrolizumab monotherapie heeft een goede anti-tumoractiviteit bij blaastumoren die geen respons vertonen op blaasspoelingen met Bacillus Calmette-Guerin pembrolizumab effectief bij niet zonder https://www.themednet.org/are-there-circumstances-where-you-would-recommend-every-6-week-dosing-schedule-for-pembrolizumab-monotherapy?from=oncology Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab... Physician discussion: Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?. See expert answers and... dosing schedule circumstances would recommend every https://www.survivornet.com/clinical-trials/melanoma/lenvatinib-plus-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-naive-metastatic-uveal-melanoma/ Melanoma Clinical Trial: Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor... Nov 8, 2023 - Melanoma - A Phase II Clinical Trial Evaluating The Combination Of Lenvatinib Plus Pembrolizumab In Patients With Treatment Naive Metastatic Uveal clinical trial immune checkpoint melanoma plus pembrolizumab https://avesis.hacettepe.edu.tr/yayin/fc3eb336-7dae-4ceb-a83d-6e4d5e9459ad/vibostolimab-coformulated-with-pembrolizumab-versus-pembrolizumab-alone-as-adjuvant-therapy-for-high-risk-stage-iibiv-melanoma-keyvibe-010-a-randomised-double-blind-phase-3-study Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for... adjuvant therapy pembrolizumab versus alone https://boris-portal.unibe.ch/entities/publication/621a2804-e410-4bfb-840c-dd18a048d631 Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer... BACKGROUND HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast... breast cancer pembrolizumab plus resistant advanced https://ricerca.uniba.it/handle/11586/434840 Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients... real world first line effectiveness pembrolizumab therapy https://www.lung.org/research/clinical-trials/find-a-clinical-trial-1/listings/pembrolizumab-immunotherapy Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic... The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with... pembrolizumab immunotherapy drug combination epigenetic https://krishgen.com/product-tag/anti-pembrolizumab/ Anti-Pembrolizumab Archives - Krishgen Biosystems krishgen biosystems anti pembrolizumab archives https://mednorge.com/tag/keytruda-pembrolizumab-medisinering Keytruda (pembrolizumab) medisinering - Med Norge keytruda pembrolizumab med norge https://app.quri.ai/trials/NCT05903833/pembrolizumab-combination-with-lenvatinib-in-pts-with-recurr Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally... Connect with this clinical trial through Quri.ai's free matching service. Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic... pembrolizumab combination pts recurrent persistent https://www.jadpro.com/education/fda-focus/2026/keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-plus-berahyaluronidase-alfa-pmph-with-paclitaxel-for-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma/ JADPRO | Keytruda pembrolizumab and Keytruda Qlex pembrolizumab plus berahyaluronidase alfa-pmph... keytruda pembrolizumab qlex plus alfa https://researchworks.creighton.edu/esploro/outputs/journalArticle/Randomized-Double-Blind-Phase-II-Study-of/991006261835302656 Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line... Jun 1, 2020 - Platinum-based chemotherapy for first-line treatment of metastatic urothelial cancer is typically administered for a fixed duration followed by observation... double blind phase ii first line study maintenance https://www.cirm.ca.gov/cirm-trial/ccl21-gene-modified-dendritic-cell-vaccine-and-pembrolizumab-in-treating-patients-with-stage-iv-non-small-cell-lung-cancer-2/ CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV... gene modified cell vaccine pembrolizumab https://www.ispor.org/vih-articles/Volume-25--Supplemental-Issue-12S/EE651-Cost-Effectiveness-Analysis-of-Pembrolizumab-Plus-Chemotherapy-in-the-First-Line-Treatment-of-Patients-With-Metastatic-Triple-Negative-Breast-Cancer-in-Greece EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of... in the first cost effectiveness analysis pembrolizumab plus https://pure.amsterdamumc.nl/en/publications/cost-effectiveness-of-pembrolizumab-monotherapy-for-high-programm/ Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or... cost effectiveness pembrolizumab high programmed death https://www.mesothelioma-line.com/pembrolizumab-plus-lenvatinib-as-second-line-treatment-in-patients-with-pleural-mesothelioma-pemmela-cohort-2-of-a-single-arm-phase-2-study/ Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma... Jan 12, 2026 - The Lancet. Oncology 2025 December [Link] Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas,... second line pleural mesothelioma pembrolizumab plus treatment https://www.mountsinai.org/about/newsroom/2019/asco-2019-randomized-doubleblind-phase-ii-study-of-maintenance-pembrolizumab-versus-placebo-after-firstline-chemotherapy-in-patients-with-metastatic-urothelial-cancer-hcrn-gu14182 "ASCO 2019: Randomized Double-blind Phase II Study of Maintenance Pembrolizumab Versus Placebo... double blind phase ii asco study maintenance https://powerfulpatients.org/tag/pembrolizumab-keytruda/ pembrolizumab (Keytruda) Archives - Patient Empowerment Network patient empowerment pembrolizumab keytruda archives network https://www.pharmanow.live/latest-news/samsung-bioepis-sb27-pembrolizumab-biosimilar-phase-1-pk-endpoints Samsung Bioepis SB27 Pembrolizumab Biosimilar Phase 1 PK | Pharma Now Samsung Bioepis' SB27 met Phase 1 PK bioequivalence endpoints in NSCLC patients. What CMC and regulatory teams need to track as the pembrolizumab biosimilar... samsung pembrolizumab biosimilar phase pk https://dzl.de/klinische-studien/this-study-will-evaluate-the-effect-of-canakinumab-or-pembrolizumab-given-as-monotherapy-or-in-combination-as-neo-adjuvant-treatment-for-subjects-with-early-stages-nsclc-canopy-n/ This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in... The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or... this study the effect evaluate pembrolizumab given https://bpno.se/medtalks/transforming-bladder-cancer-treatment-with-enfortumab-vedotin-and-pembrolizumab/ Transforming Bladder Cancer Treatment with Enfortumab Vedotin and Pembrolizumab May 5, 2026 - Christof Vulsteke, Head of the Integrated Cancer Center Ghent (IKG) in Belgium, presents new phase III data highlighting a paradigm shift in muscle-invasive... bladder cancer treatment transforming pembrolizumab https://bpno.fi/artikkelit/sabcs20-positive-results-of-pembrolizumab-in-1l-for-triple-negative-breast-cancer-regardless-of-chemotherapy-partner/ Positive results of pembrolizumab in 1L for triple negative breast cancer regardless of... Mar 21, 2022 - A subgroup analysis from the Phase 3 study Keynote 355 presented at SABCS shows that first-line treatment with the immunotherapy pembrolizumab in combination... triple negative breast positive results pembrolizumab cancer regardless https://www.irst.emr.it/it/pubblicazioni/optimizing-the-use-of-lenvatinib-in-combination-with-pembrolizumab-in-patients-with-advanced-endometrial-carcinoma Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced... Frontiers in oncology optimizing use combination pembrolizumab patients https://www.mayo.edu/research/clinical-trials/cls-20306547 Pembrolizumab And Ibrutinib In Treating Patients With Stage III-IV Melanoma That Cannot Be Removed... Learn more about services at Mayo Clinic. pembrolizumab ibrutinib treating patients stage https://air.unipr.it/handle/11381/2992774 Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from... in patients efficacy perioperative pembrolizumab treatment https://www.em-consulte.com/article/1170839?prompt=false First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or... First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre,... first line pembrolizumab cisplatin ineligible patients https://ogkologos.com/fda-grants-accelerated-approval-to-pembrolizumab-for-locally-recurrent-unresectable-or-metastatic-tnbc/ FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic... fda grants accelerated approval pembrolizumab https://augusta.elsevierpure.com/en/publications/phase-ii-trial-of-the-ido-pathway-inhibitor-indoximod-plus-pembro/ Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of... phase ii trial ido pathway inhibitor https://www.allclinicaltrials.com/study/NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy... This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic... the addition testing pembrolizumab immunotherapy cancer https://research-repository.uwa.edu.au/en/publications/seven-year-analysis-of-adjuvant-pembrolizumab-versus-placebo-in-s-2/fingerprints/?sortBy=alphabetically Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325... seven year analysis adjuvant pembrolizumab https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic... first line fda approves pembrolizumab combination